Nuvectis Pharma rises on FDA nod for cancer therapy

Nuvectis Pharma

21/06/2022 18:34

** Shares of drugmaker Nuvectis Pharma  NVCT.O  rise 13.6%
to $12.50, on track to mark their third straight session of
gains
    ** Co says U.S. FDA has cleared its investigational new drug
(IND) application for its experimental cancer therapy NXP800
 urn:newsml:reuters.com:*:nFWN2Y809U
    ** NVCT also expects to initiate expansion study (phase 1b)
for the same therapy in early 2023
    ** Earlier in June, co had reported positive data from its
study of its other cancer therapy product NXP900  urn:newsml:reuters.com:*:nFWN2Y0096
    ** NVCT has risen more than threefold since going public in
February, as of last close

 (Reporting by Raechel Thankam Job)
 ((RaechelThankam.Job@thomsonreuters.com;))